Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.

about

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.

Item

http://www.wikidata.org/entity/Q38637958

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current status on the place of ...... cancer and future directions.

@en

type

Item

label

Current status on the place of ...... cancer and future directions.

@en

prefLabel

Current status on the place of ...... cancer and future directions.

@en

P1476

Current status on the place of ...... cancer and future directions.

@en

P2093

Aurélien Lambert

http://www.w3.org/2001/XMLSchema#string

Céline Gavoille

http://www.w3.org/2001/XMLSchema#string

Thierry Conroy

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

New Advances in the Treatment of Metastatic Pancreatic Cancer

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.

P304

631-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X17713879

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28835777

http://www.w3.org/2001/XMLSchema#string

P932

5557187

http://www.w3.org/2001/XMLSchema#string